Acetyl-Calpastatin (184-210) (human)
Cat. No. 2950
Biological ActivitySelective calpain inhibitor. Strongly inhibits calpain I (Ki = 0.2 nM) and II but does not inhibit papain, trypsin and cathepsin L (Ki = 6 μM). Increases secretion of amyoid β-protein (Aβ) 42, Aβ40 and Aβ42 ratio.
(Modifications: Asp-1 = N-terminal Ac, Ala-27 = C-terminal amide)
The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Certificate of Analysis / Safety Data Sheet
Maki et al (1989) Inhibition of calapin by a synthetic oligopeptide corresponding to an exon of the human calpastatin gene. J.Biol.Chem. 264 18866. PMID: 2553724.
Yamazaki et al (1997) Specific increase in amyloid β-protein 42 secretion ratio by calpain inhibition. Biochem. 36 8377.
Fiorino et al (2007) A new cell-permeable calpain inhibitor. J.Peptide Sci. 13 70.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: Acetyl-calpastatin 184-210 (human), supplier, Selective, calpain, inhibitors, Ca2+Sensitive, Protease, modulators, Calcium-Sensitive, Ca2+, Signaling, Signalling, Proteinases, Proteases, Acetyl-calpastatin184-210, (human)
Find multiple products by catalog number
New Products in this Area
γ-secretease inhibitor; inhibits Notch pathwayCA 074
Selective cathepsin B inhibitorP005091
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.